… All ROCs are statistically different from the random predictor line (… a Relapse-free survival
(RFS) of patients according to … occurring on donor cells cannot be detected by chimerism, as …

… long progression-free survival (PFS), but measurable residual … Society for Blood and Marrow
Transplantation (EBMT) of … set while keeping age, donor type, and donor-recipient gender …

… full donor chimerism experienced disease progression. In … The 4-year progression-free
survival in the MMC cohort was … 12 months, when the indication was relapse rather than GF (due …

… survival (OS) and relapse-free survival, whereas mixed CD33 + … /host chimerism at various
timepoints post-HCT were available. … A time-dependent indicator variable was used to define …

… on disease recurrence in patients with acute myeloid leukemia (AML) … rate of disease
recurrence, progression free survival was … We found that CD3 chimerism form the haplo-donor was …

… However, even in chronic myelogenous leukemia, results … Full donor chimerism was defined
by the absence of any … from acute myeloid leukemia (AML, 78%) or acute lymphoblastic …

… In 2021, the European Blood and Marrow Transplantation (… F and G Comparison of donor
chimerism measured by NGS … of overt relapse, relapse-free survival, and overall survival by …

… , oncology, blood, and marrow transplantation unit. We included … (MPAL) and chronic myeloid
leukemia (CML) in blast crisis … donor chimerism on Day+60 from the bone marrow sample. …

… bone marrow (BM), while 14 patients were transplanted with … donor-derived hematopoiesis,
we performed chimerism … at diagnosis of chronic phase chronic myeloid leukemia (CML…

… status, bone marrow fibrosis, spleen size, donor chimerism, … differences in relapse-free
survival (RFS) and overall survival (… identified as indicators of measurable residual disease and …